Cassava Sciences is an US clinical -stage biotechnology company. The company detects and treats neurodegenerative diseases such as alzheimer’s. Because the companies pre revenue status usual financial valuations like the DCF or NPV used in order to derive the value of the company aren’t applicable, this pitch will heavily focus on the clinical and chemical inneficienciesThe thesis of this work is based on the fact that $SAVA has only one potential drug (Simufilam) candidate in its pipeline, making the success of the company largely dependent on the clinical results of this drug. Unlike the overall positive analyst consensus and recent stock price hike (due to a new CEO) I remain extremely bearish on the future of $SAVA.

$SAVA has published the

Whats drug

What says the clinical data---- P Values, Adverse Events

What is their past

And what even if they’ll get the approval

Are those couple of percents less adverse Events worth this little bit bettering conditions

Is it healingmore rapid than it is killing

CEO Change caused a spike upwards